David A. Scheinberg

David A. Scheinberg is an American physician, scientist, drug developer, and entrepreneur, who is currently Vincent Astor Chair, and Chairman of the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSK).[1] He is a pioneer and inventor of targeted alpha particle therapies and alpha particle generators for use in patients with cancer.[2][3]

David A. Scheinberg
EducationCornell University BA Johns Hopkins University School of Medicine MD, PhD
Medical career
ProfessionPhysician-scientist
InstitutionsMemorial Sloan Kettering Cancer Center
Weill Cornell Medicine
Sub-specialtiesLeukemia

Career

Scheinberg received a BA from Cornell University and an MD, PhD from Johns Hopkins University School of Medicine. He is a professor of pharmacology and co-chair of the pharmacology graduate program at Weill Cornell Graduate School of Medical Sciences and a professor at the Gerstner Sloan Kettering Graduate School. He also founded and chairs the Experimental Therapeutics Center and formerly the Nanotechnology Center at MSK. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Weill Cornell Medicine, and Rockefeller Universities.

In 2013 Nature Biotechnology recognized him as one of the top 20 Translational Scientists in the world.[4] Scheinberg has published more than 300 papers, chapters, or books and has more than 30 patents.

His laboratory studies cancer immunology, cellular engineering, cancer vaccines, T cell receptor mimic antibodies, and targeted nano-machines.

Memberships

Awards
  • Doris Duke Distinguished Clinical Science Professorship
  • Lucille P. Markey Scholarship
  • Emil J. Freireich Award
  • Leukemia and Lymphoma Society Translational Investigator Awards
  • CapCure Awards

References
  1. "At Work: Center for Experimental Therapeutics Chair David Scheinberg | Memorial Sloan Kettering Cancer Center". www.mskcc.org.
  2. Scheinberg, D. A.; Strand, M.; Gansow, O. A. (1982-03-19). "Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies". Science. 215 (4539): 1511–1513. Bibcode:1982Sci...215.1511S. doi:10.1126/science.7199757. ISSN 0036-8075. PMID 7199757.
  3. McDevitt, Michael R.; Ma, Dangshe; Lai, Lawrence T.; Simon, Jim; Borchardt, Paul; Frank, R. Keith; Wu, Karen; Pellegrini, Virginia; Curcio, Michael J. (2001-11-16). "Tumor Therapy with Targeted Atomic Nanogenerators". Science. 294 (5546): 1537–1540. Bibcode:2001Sci...294.1537M. doi:10.1126/science.1064126. ISSN 0036-8075. PMID 11711678. S2CID 11782419.
  4. Huggett, Brady; Paisner, Kathryn (2014-08-07). "Top 20 translational researchers in 2013". Nature Biotechnology. 32 (8): 720. doi:10.1038/nbt.2986. PMID 25101739.
  5. "David Scheinberg ASCI".
  6. "David Scheinberg AAP".
  7. "Interurban Clinical Club Members".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.